ACP
Acuta Capital Partners Portfolio holdings
AUM
$71.6M
This Quarter Return
+39.51%
1 Year Return
+169.78%
3 Year Return
+1,553.75%
5 Year Return
+4,509.01%
10 Year Return
+155,159.98%
AUM
$340M
AUM Growth
+$340M
(-1.7%)
Cap. Flow
-$44M
Cap. Flow
% of AUM
-12.92%
Top 10 Holdings %
Top 10 Hldgs %
53.95%
Holding
62
New
15
Increased
11
Reduced
11
Closed
19
Top Buys
| 1 |
SAGE
Sage Therapeutics
SAGE
|
$13.8M |
| 2 |
CMPS
Compass Pathways
CMPS
|
$13.6M |
| 3 |
TRIL
Trillium Therapeutics Inc.
TRIL
|
$12.1M |
| 4 |
89bio
ETNB
|
$10.7M |
| 5 |
Celldex Therapeutics
CLDX
|
$8.08M |
Top Sells
| 1 |
Adverum Biotechnologies
ADVM
|
$36.5M |
| 2 |
BioXcel Therapeutics
BTAI
|
$18.1M |
| 3 |
ADAP
Adaptimmune Therapeutics
ADAP
|
$11.7M |
| 4 |
Iovance Biotherapeutics
IOVA
|
$9.05M |
| 5 |
Ascendis Pharma
ASND
|
$8.21M |
Sector Composition
| 1 | Healthcare | 79.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
IMMU
1
DELISTED
Immunomedics Inc
IMMU
| $43.5M | 11.81% | 511,500 -33,500 | -6% | -$2.85M |
|
2
Kura Oncology
KURA
$686M
| $29.8M | 8.1% | 973,000 +100,500 | +12% | +$3.08M |
|
|
3
Celldex Therapeutics
CLDX
$1.47B
| $22.9M | 6.22% | 1,545,000 +545,000 | +55% | +$8.08M |
|
|
SAGE
4
DELISTED
Sage Therapeutics
SAGE
| $13.8M | 3.73% | +225,000 | New | +$13.8M |
|
|
CMPS
5
Compass Pathways
CMPS
$424M
| $13.6M | 3.7% | +390,000 | New | +$13.6M |
|
6
Larimar Therapeutics
LRMR
$310M
| $12.6M | 3.42% | 830,000 +6,831 | +0.8% | +$104K |
|
7
Mersana Therapeutics
MRSN
$36.5M
| $12.4M | 3.38% | 667,500 +35,000 | +6% | +$652K |
|
8
Aldeyra Therapeutics
ALDX
$351M
| $12.2M | 3.31% | 1,646,700 +756,700 | +85% | +$5.61M |
|
|
TRIL
9
DELISTED
Trillium Therapeutics Inc.
TRIL
| $12.1M | 3.29% | +853,000 | New | +$12.1M |
|
|
10
89bio
ETNB
$1.34B
| $10.7M | 2.91% | +417,500 | New | +$10.7M |
|
11
Relmada Therapeutics
RLMD
$37.2M
| $10.4M | 2.83% | 277,000 +42,500 | +18% | +$1.6M |
|
|
12
Iovance Biotherapeutics
IOVA
$807M
| $10.4M | 2.82% | 315,000 -275,000 | -47% | -$9.05M |
|
13
Altimmune
ALT
$338M
| $9.08M | 2.47% | 688,000 +150,500 | +28% | +$1.99M |
|
14
Immunovant
IMVT
$2.56B
| $8.8M | 2.39% | 250,000 -100,000 | -29% | -$3.52M |
|
15
Cytokinetics
CYTK
$4.23B
| $7.74M | 2.1% | +357,500 | New | +$7.74M |
|
16
RAPT Therapeutics
RAPT
$188M
| $7.73M | 2.1% | +240,000 | New | +$7.73M |
|
|
LSACU
17
DELISTED
LifeSci Acquisition Corp. Unit 1 COM & 1 WT
LSACU
| $7.62M | 2.07% | 560,000 | – | – |
|
|
SURF
18
DELISTED
Surface Oncology, Inc. Common Stock
SURF
| $7.51M | 2.04% | 1,088,000 +863,000 | +384% | +$5.95M |
|
19
Athira Pharma
ATHA
$15.3M
| $6.69M | 1.82% | +362,500 | New | +$6.69M |
|
20
Avidity Biosciences
RNA
$5.99B
| $6.62M | 1.8% | 235,000 +117,500 | +100% | +$3.31M |
|
21
Gyre Therapeutics
GYRE
$703M
| $6.44M | 1.75% | 1,497,900 | – | – |
|
22
Cartesian Therapeutics
RNAC
$261M
| $5.86M | 1.59% | 2,364,204 | – | – |
|
|
CBAY
23
DELISTED
Cymabay Therapeutics
CBAY
| $5.54M | 1.5% | +765,000 | New | +$5.54M |
|
24
Apellis Pharmaceuticals
APLS
$3.48B
| $5.04M | 1.37% | 167,054 -22,946 | -12% | -$692K |
|
|
ISEE
25
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $4.53M | 1.23% | 802,500 +115,000 | +17% | +$649K |
|